UniQure leads genetic medicine biotech rally after news of Prasad’s exit

Vinay Prasad contributed to an uncertain regulatory climate for gene therapy makers focused on rare conditions. Shares of many developers rose on the chance of a more industry-friendly successor.

By Jacob Bell • March 9, 2026

Ipsen to withdraw cancer drug acquired in buyout due to safety concerns

Ipsen found cases of secondary malignancies in a confirmatory study of Tavzerik, a medicine it got in a purchase of Epizyme and that it has struggled to sell. 

By Delilah Alvarado • March 9, 2026

Explore the Trendline➔

Emerging biotech

New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

By BioPharma Dive staff

Servier to build cancer drug pipeline with $2.5B purchase of Day One

The proposed acquisition would hand Servier a couple experimental drugs in human testing as well as Ojemda, an approved therapy for certain hard-to-treat brain tumors that affect children.

By Jacob Bell • March 6, 2026

Pfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs

The clearance in China comes weeks after Pfizer acquired rights to the therapy. Elsewhere, Alnylam is looking for “novel” cardiovascular targets and investors sold off Helus shares. 

By BioPharma Dive staff • March 6, 2026

A startup making drugs for blood disorders banks $160M

Atavistik Bio is using the cash to develop “allosteric” medicines it believes can precisely impact on diseases like myelofibrosis and the blood condition HHT.

By Gwendolyn Wu • March 5, 2026

Moderna to pay up to $2.25B to end mRNA vaccine patent fight

Announced days before a trial, the deal settles a longstanding dispute and avoids what one analyst called a “worst-case scenario” financially for Moderna.

By Delilah Alvarado • March 4, 2026

FDA again targets GLP-1 compounders; Intellia to restart heart disease trial

The agency zeroed in on claims that compounded GLP-1 drugs are comparable to approved medicines. Elsewhere, a blood pressure drug topped Wall Street expectations and a Merck deal paid dividends.

By Ben Fidler • March 4, 2026

Kyowa Kirin abandons touted eczema drug following safety review

A month after Amgen gave up on rocatinlimab — which was once seen as a threat to Dupixent — new findings have linked the drug’s mechanism to the onset of a type of skin cancer.

By Delilah Alvarado • March 3, 2026

UniQure says FDA wants another study of Huntington’s gene therapy

Agency staff "strongly recommended" a sham surgery-controlled trial be conducted before an approval filing, a stance one analyst called a "worst case scenario" for UniQure.

By Jacob Bell • March 2, 2026

Candid, in a reverse merger with RallyBio, to go public

Candid, which is making bispecifics for immune diseases, has also raised $505 million in a private financing for the newly formed company.

By Gwendolyn Wu • March 2, 2026

Why it’s critical to close open steps in cell therapy manufacturing

Reduce risk, cut costs and scale smarter by closing open steps in cell therapy manufacturing.

March 2, 2026

Atrium spins out of Avidity, aiming to target rare heart diseases with RNA

Four months after Avidity’s $12 billion buyout, Atrium debuted with $270 million in cash and plans to pick up its predecessor’s work in cardiovascular disease.

By Ben Fidler • Feb. 27, 2026

UniQure falls further on Makary comments

Remarks the FDA commissioner made during a CNBC appearance seemed to stoke investor fears that UniQure's gene therapy for Huntington's won't get approved.

By Jacob Bell • Feb. 27, 2026

Moderna’s combination flu, COVID shot wins over European drug regulators

In issuing a positive recommendation, the EMA has diverged from the FDA, which has set higher approval standards for Moderna’s vaccine in the U.S. 

By Delilah Alvarado • Feb. 27, 2026

Generate caps a strong month for biotech IPOs with $400M offering

The AI drug discovery specialist is the fifth biotechnology company to go public in February and priced the sector’s largest new stock offering in nearly three years.

By Gwendolyn Wu • Feb. 26, 2026

Boehringer drug approved in 44 days; BioMarin shelves Roctavian

Boehringer’s lung cancer medicine Hernexeos is the second “national priority” voucher winner to gain a speedy approval. Elsewhere, a landmark gene therapy was withdrawn and a Pfizer deal paid dividends.

By BioPharma Dive staff • Feb. 26, 2026

Sarepta CEO Doug Ingram to retire, with company at a crossroads

Ingram, who steered the company through multiple drug approvals and controversies, will step aside as Sarepta faces dwindling Elevidys sales and emerging competitors to its core business. 

By Ben Fidler • Feb. 26, 2026

Alkermes’ Richard Pops to step down after three-decade run as CEO

One of biotech’s longest-tenured leaders, Pops steered Alkermes through several reinventions, the latest of which has made it a frontrunner in developing a new narcolepsy drug.

By Jonathan Gardner • Feb. 25, 2026

With Vivtex deal, Novo gains a chance at better oral obesity drugs

The potentially $2.1 billion collaboration gives Novo access to technologies that are meant to help optimize the delivery of oral biologic medicines. 

By Gwendolyn Wu • Feb. 25, 2026

BreezeBio banks $60M to make more precise genetic medicines

The company has shed its former “GenEdit” name and strategy in favor of a plan to develop its own medicines, starting with a potential tolerance-inducing treatment for Type 1 diabetes.

By Gwendolyn Wu • Feb. 25, 2026

Vir climbs on Astellas deal, study results for ‘masked’ T cell engager

According to one analyst, the alliance and early data “validate” the oncology work of Vir, which was once purely an infectious disease specialist before changing course.

By Delilah Alvarado • Feb. 24, 2026

Novo to cut GLP-1 drug prices; Palvella soars on study data

Wegovy and Ozempic’s list prices will be reduced by as much as 50% effective next year. Elsewhere, Palvella’s market value surged past $1 billion while Pfizer nabbed rights to another obesity drug.

By BioPharma Dive staff • Feb. 24, 2026

Slate starts up with $130M and a headache drug from China

The biotech is developing a drug aimed at a protein called PACAP, which has emerged as a potentially new way to prevent the onset of migraines.

By Gwendolyn Wu • Feb. 24, 2026

Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi

Madrigal shares fell 11% despite again topping consensus sales numbers. Elsewhere, Daiichi Sankyo named a new research chief and J&J halted recruitment in an Alzheimer’s trial. 

By Ben Fidler • Feb. 20, 2026

AI is slashing jobs across industries. Will pharma be next?

Despite a wave of AI-fueled layoffs, the pharma and biotech industries could be spared from massive cutbacks for now.

By Alexandra Pecci • Feb. 20, 2026